{"publication_id":"882d6167-8336-4714-87b4-501263f7898e","screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted alpha memo, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["This receipt-backed scoping note has one bounded signal: acarbose shows context-dependent, not convergent, associations across this 5-source primary bundle (2013-2020). Grouped by direction, directionally favorable: 8-week treatment with acarbose significantly decreased fasting blood glucose; The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose... | other/mixed: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; 8-week treatment with acarbose significantly decreased fasting blood glucose; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005).","other/mixed: Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone — The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005)","other/mixed: Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. — Acarbose increased male median lifespan by 22% (P < 0.0001)"]}